Verification evidence is still being completed.
PDF / print export
TolerogenixX
Heidelberg, Germany
- Verified lead
- Matthias Schaier
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
- Review cycle
- May 2026
- Full address
- Im Neuenheimer Feld 582, 69120 Heidelberg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official TolerogenixX contact page confirming the Heidelberg address.
- Editorial note
- TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
Official leadership disclosure, Official Heidelberg address disclosure, Cell-therapy platform claim
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Heidelberg, Germany
TolerogenixX
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development · Clinical-stage cell-therapy platform
Verified 22 Mar 2026 · 2 sources
Cell TherapyClinical
TolerogenixX runs cell-therapy development, autoimmune disease programs, and transplant-related tolerance programs in Heidelberg, Germany.
Contact & location
- Website
- tolerogenixx.com
- Company page
- Lead
- Matthias Schaier (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (4mo ago)
- Scale
- Clinical-stage cell-therapy platform
- Capabilities
- Cell-Therapy Development · Autoimmune Disease Programs · Transplant-Related Tolerance Programs
- Founded
- 2014
- Headcount
- 11-50
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Editorial note
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Verification details
Clinical profileSTATUS: VERIFIED MARCH 2026
Matthias Schaier
Chief Executive Officer
Full addressIm Neuenheimer Feld 582, 69120 Heidelberg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage cell-therapy platform
Heidelberg, Germany. Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development. Review completed on 22 Mar 2026.
German corporate and advanced-therapy oversight
Official leadership disclosure, Official Heidelberg address disclosure, Cell-therapy platform claim
Capabilities
Cell-Therapy Development
Autoimmune Disease Programs
Transplant-Related Tolerance Programs
Sources
The official sources used to verify this profile.
Infrastructure
Cell-processing workflow
ATMP development systems
Clinical program infrastructure
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
Frequently asked questions
- Where is TolerogenixX located?
- TolerogenixX operates from Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, Heidelberg, Germany.
- Who runs TolerogenixX?
- TolerogenixX is led by Matthias Schaier, Chief Executive Officer. Verified 22 Mar 2026.
- What does TolerogenixX do?
- TolerogenixX runs cell-therapy development, autoimmune disease programs, and transplant-related tolerance programs in Heidelberg, Germany. Core capabilities: Cell-Therapy Development, Autoimmune Disease Programs, Transplant-Related Tolerance Programs.
Editorial context
Related technical briefs
Briefs that name Heidelberg as a covered market or city.